Alemtuzumab has been extensively used in the salvage setting of chronic lymphocytic leukemia (CLL) resulting less effective on bulky lymphadenopathy. 1 Higher response rates have been achieved when combined with fludarabine and cyclophosphamide (FC), but this regimen has led to some safety challenges both in first-line and relapsed settings. 2, 3, 4 Compared to FC, bendamustine shows a better safety profile including a lower rate of myelosuppression and infective complications [5] [6] [7] and turns out to be an ideal chemotherapy to be challenged in combination with alemtuzumab (BenCam). To define the efficacy and tolerability of the combination bendamustine intravenous (IV) day 1,2 and alemtuzumab subcutaneous (SC) day 1-3 we conducted an Italian multicentric, single arm, open label, phase I/II study in relapsed and refractory CLL following at least one line of treatment including alkylating agents or purine analogs, alone or in combination.
Refractoriness was defined as treatment failure or disease progression within 6 months to the last antileukemic therapy.
In the first phase standard 3+3 stepwise dose-escalation design was planned to identify dose-limiting toxicity (DLT) and maximum tolerated dose (MTD Prophylaxis with co-trimoxazole and acyclovir was administered throughout treatment and for at least 3 months after treatment discontinuation. Granulocyte colony-stimulating factor (G-CSF) and erythropoietin were permitted at clinician's discretion. CMV DNA was monitored weekly by PCR during treatment and for the following 6 weeks after treatment discontinuation. BenCam combination treatment in a heavily CLL pretreated population led to an high rate of good quality responses translating in a prolonged PFS and TTR. Responses after
BenCam were independent from previous type and lines of treatment and it is worth noting that most of the patients had previously received combination treatment with monoclonal antibodies. Furthermore the ORR was independent of IGHV gene mutational status, NOTCH1 or SF3B1 mutations, though for the latter only few positive cases were found in our series. The absence of a prognostic impact of these mutations could depend on alemtuzumab activity as recently reported in CLL2H trial.
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Responses in patients with 17pdel/TP53 mutation were consistent (57%), comparing favourably to regimens including anti CD20 monoclonal antibody therapy either with FC (35%) 12 or B (rituximab 7.1%, ofatumumab 37%). 6, 13 BenCam was well tolerated without unexpected toxicities being manageable even during dose-escalation phase as MTD corresponded to the highest level. Of interest only 16% of patients discontinued treatment due to toxicity and no dose reductions were performed during treatment. The intended courses were administered in comparable percentages The FCR combination showed to be poorly tolerated as only a minority of patients (42%), in particular the elderly, completed the intended courses. 12 Better compliance was observed in the REACH trial but patients previously treated with FC or rituximab were excluded from this study. 15 Bendamustine in combination with Rituximab given in the salvage setting demonstrated to be less toxic than FCR but allowed to achieve an ORR and CR rate of only 59% and 9%
respectively. 6 Overall response and CR rates observed in our study are superior and have been obtained in patients that in the vast majority had received immunochemotherapy.
Furthermore, in our series infection rate was not superior to that observed after rituximab in combination with FC or bendamustine administered in the same setting. 6, 12 Even if Bendamustine and Alemtuzumab showed to effectively overcome poor prognostic characteristics conferred by del11q and trisomy 12, it obtained shorter response duration in cases with 17pdel/TP53 mutation. This confirms that patients carrying this genomic aberration still remain a challenge, warranting further investigation to find the most appropriate treatment.
PFS and OS in the entire group of patients treated with BenCam were in line with those observed after BR and FCR 6, 12 To explain the longer PFS observed after FCC salvage treatment we must emphasize that only 13% of patients treated with FCC had previously received monoclonal antibodies compared to 70% of those in the BenCam trial. 
